首页|高压氧联合艾司唑仑治疗伴焦虑症慢性失眠效果及对炎性细胞相关因子的作用

高压氧联合艾司唑仑治疗伴焦虑症慢性失眠效果及对炎性细胞相关因子的作用

扫码查看
目的 探究高压氧联合艾司唑仑对慢性失眠伴焦虑症患者的效果及对炎性细胞因子的作用机制.方法 选取2021年5月至2023年3月安阳市人民医院144例慢性失眠伴焦虑症患者,采用随机数字表法分为联合组、艾司唑仑组、高压氧组,各48例.艾司唑仑组采用艾司唑仑治疗,高压氧组采用高压氧治疗,联合组采用高压氧联合艾司唑仑治疗.比较三组治疗效果、不良反应发生情况,并比较三组治疗前后焦虑情绪(SAS评分)、睡眠质量(PSQI评分)、炎性细胞因子[白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)]水平、下丘脑-垂体-肾上腺轴(HPA轴)相关因子[促肾上腺皮质激素释放激素(CRH)、促肾上腺皮质激素(ACTH)]水平.结果 联合组治疗总有效率高于艾司唑仑组、高压氧组,差异有统计学意义(x2=6.486,P<0.05);联合组治疗后SAS、PSQI评分低于艾司唑仑组、高压氧组,差异有统计学意义(F=25.124、6.277,P<0.05);联合组治疗后IL-1β、TNF-α水平低于艾司唑仑组、高压氧组,差异有统计学意义(F=181.225、482.978,P<0.05);联合组治疗后血浆CRH、ACTH水平低于艾司唑仑组、高压氧组,差异有统计学意义(F=7.829、3.986,P<0.05);联合组不良反应总发生率(4.17%)与艾司唑仑组(6.25%)、高压氧组(2.08%)比较,差异无统计学意义(x2=1.044,P>0.05).结论 高压氧联合艾司唑仑是治疗慢性失眠伴焦虑症患者的有效方案,能显著改善患者睡眠质量和心理状态,其分子机制可能与调节炎性细胞因子、HPA轴相关因子有关.
Effect of hyperbaric oxygen combined with esomeprazole in the treatment of chronic insomnia with anxiety and its effect on inflammatory cell related factors
Objective To investigate the effect of hyperbaric oxygen combined with estazolam on patients with chronic insomnia accompanied by anxiety and its mechanism of action on inflammatory cytokines.Methods 96 patients with chronic insomnia and anxiety at Anyang People's Hospital from May 2021 to March 2023 were selected and divided into a study group and a control group by random number table,with 48 cases in each group.The control group received treatment with estazolam,and the study group was treated with hyperbaric oxygen combined with estazolam.The therapeutic effects and adverse reactions of the two groups were compared,and the anxiety (SAS score),sleep quality (PSQI score),inflammatory cytokine lev-els[interleukin-1β (IL-1β),tumor necrosis factor-α (TNF-α)],and hypothalamic-pituitary-adrenal axis (HPA axis) related factors[corticotropin-releasing hormone (CRH),adrenocorticotropic hormone (ACTH)]levels before and after treatment were compared between the two groups.Results The total effective rate of the treatment group was higher than that of the control group,and the difference was statistically significant (x2=4.360,P<0.05).The SAS and PSQI scores after treatment in the treatment group were lower than those in the control group,and the differences were statistically significant (t=6.087,2.895,P<0.05).The levels of IL-1β and TNF-α after treatment in the treatment group were lower than those in the control group,and the dif-ferences were statistically significant (t=3.579,7.291,P<0.05).The levels of plasma CRH and ACTH after treatment in the treatment group were lower than those in the control group,and the differences were statisti-cally significant (t=3.255,2.340,P<0.05).The total incidence of adverse reactions in the treatment group (4.17%) was not significantly different from that in the control group (6.25%),and the difference was not sta-tistically significant (x2=0.000,P>0.05).Conclusion Hyperbaric oxygen therapy combined with estazolam is an effective treatment for patients suffering from chronic insomnia and anxiety.This combination can signifi-cantly improve both sleep quality and psychological status.The molecular mechanism behind this treatment's success may be related to the regulation of inflammatory cytokines and factors related to the HPA axis.

Chronic insomniaAnxiety disorderHyperbaric oxygenEstazolamHypothalamic-pituitary-adrenal axis

邓越峰、乔志敏、李积梅、董雪柯、郭艳平

展开 >

河南省安阳市人民医院医学心理科,河南,安阳455000

安阳市人民医院神经内科,河南,安阳455000

慢性失眠 焦虑症 高压氧 艾司唑仑 下丘脑-垂体-肾上腺轴

河南省医学科技攻关计划

LHGJ20191269

2024

分子诊断与治疗杂志
中山大学

分子诊断与治疗杂志

CSTPCD
影响因子:0.65
ISSN:1674-6929
年,卷(期):2024.16(7)